RT Journal Article
T1 Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
A1 Gaziano, Liam
A1 Sun, Luanluan
A1 Arnold, Matthew
A1 Bell, Steven
A1 Cho, Kelly
A1 Kaptoge, Stephen K
A1 Song, Rebecca J
A1 Burgess, Stephen
A1 Posner, Daniel C
A1 Mosconi, Katja
A1 Robinson-Cohen, Cassianne
A1 Mason, Amy M
A1 Bolton, Thomas R
A1 Tao, Ran
A1 Allara, Elias
A1 Schubert, Petra
A1 Chen, Lingyan
A1 Staley, James R
A1 Staplin, Natalie
A1 Altay, Servet
A1 Amiano, Pilar
A1 Arndt, Volker
A1 Ärnlöv, Johan
A1 Barr, Elizabeth L M
A1 Björkelund, Cecilia
A1 Boer, Jolanda M A
A1 Brenner, Hermann
A1 Casiglia, Edoardo
A1 Chiodini, Paolo
A1 Cooper, Jackie A
A1 Coresh, Josef
A1 Cushman, Mary
A1 Dankner, Rachel
A1 Davidson, Karina W
A1 de Jongh, Renate T
A1 Donfrancesco, Chiara
A1 Engström, Gunnar
A1 Freisling, Heinz
A1 de la Cámara, Agustín Gómez
A1 Gudnason, Vilmundur
A1 Hankey, Graeme J
A1 Hansson, Per-Olof
A1 Heath, Alicia K
A1 Hoorn, Ewout J
A1 Imano, Hironori
A1 Jassal, Simerjot K
A1 Kaaks, Rudolf
A1 Katzke, Verena
A1 Kauhanen, Jussi
A1 Kiechl, Stefan
A1 Koenig, Wolfgang
A1 Kronmal, Richard A
A1 Kyrø, Cecilie
A1 Lawlor, Deborah A
A1 Ljungberg, Börje
A1 MacDonald, Conor
A1 Masala, Giovanna
A1 Meisinger, Christa
A1 Melander, Olle
A1 Moreno Iribas, Conchi
A1 Ninomiya, Toshiharu
A1 Nitsch, Dorothea
A1 Nordestgaard, Børge G
A1 Onland-Moret, Charlotte
A1 Palmieri, Luigi
A1 Petrova, Dafina
A1 Garcia, Jose Ramón Quirós
A1 Rosengren, Annika
A1 Sacerdote, Carlotta
A1 Sakurai, Masaru
A1 Santiuste, Carmen
A1 Schulze, Matthias B
A1 Sieri, Sabina
A1 Sundström, Johan
A1 Tikhonoff, Valérie
A1 Tjønneland, Anne
A1 Tong, Tammy
A1 Tumino, Rosario
A1 Tzoulaki, Ioanna
A1 van der Schouw, Yvonne T
A1 Monique Verschuren, W M
A1 Völzke, Henry
A1 Wallace, Robert B
A1 Wannamethee, S Goya
A1 Weiderpass, Elisabete
A1 Willeit, Peter
A1 Woodward, Mark
A1 Yamagishi, Kazumasa
A1 Zamora-Ros, Raul
A1 Akwo, Elvis A
A1 Pyarajan, Saiju
A1 Gagnon, David R
A1 Tsao, Philip S
A1 Muralidhar, Sumitra
A1 Edwards, Todd L
A1 Damrauer, Scott M
A1 Joseph, Jacob
A1 Pennells, Lisa
A1 Wilson, Peter W F
A1 Harrison, Seamus
A1 Gaziano, Thomas A
A1 Inouye, Michael
A1 Baigent, Colin
A1 Casas, Juan P
A1 Langenberg, Claudia
A1 Wareham, Nick
A1 Riboli, Elio
A1 Gaziano, J Michael
A1 Danesh, John
A1 Hung, Adriana M
A1 Butterworth, Adam S
A1 Wood, Angela M
A1 Di Angelantonio, Emanuele
K1 cardiovascular diseases
K1 coronary disease
K1 kidney diseases
K1 stroke
AB End-stage renal disease is associated with a high risk of cardiovascular events. It is unknown, however, whether mild-to-moderate kidney dysfunction is causally related to coronary heart disease (CHD) and stroke. Observational analyses were conducted using individual-level data from 4 population data sources (Emerging Risk Factors Collaboration, EPIC-CVD [European Prospective Investigation into Cancer and Nutrition-Cardiovascular Disease Study], Million Veteran Program, and UK Biobank), comprising 648 135 participants with no history of cardiovascular disease or diabetes at baseline, yielding 42 858 and 15 693 incident CHD and stroke events, respectively, during 6.8 million person-years of follow-up. Using a genetic risk score of 218 variants for estimated glomerular filtration rate (eGFR), we conducted Mendelian randomization analyses involving 413 718 participants (25 917 CHD and 8622 strokes) in EPIC-CVD, Million Veteran Program, and UK Biobank. There were U-shaped observational associations of creatinine-based eGFR with CHD and stroke, with higher risk in participants with eGFR values 105 mL·min-1·1.73 m-2, compared with those with eGFR between 60 and 105 mL·min-1·1.73 m-2. Mendelian randomization analyses for CHD showed an association among participants with eGFR 105 mL·min-1·1.73 m-2. Results were not materially different after adjustment for factors associated with the eGFR genetic risk score, such as lipoprotein(a), triglycerides, hemoglobin A1c, and blood pressure. Mendelian randomization results for stroke were nonsignificant but broadly similar to those for CHD. In people without manifest cardiovascular disease or diabetes, mild-to-moderate kidney dysfunction is causally related to risk of CHD, highlighting the potential value of preventive approaches that preserve and modulate kidney function.
PB Lippincott Williams & Wilkins
YR 2022
FD 2022-08-18
LK http://hdl.handle.net/10668/20199
UL http://hdl.handle.net/10668/20199
LA en
NO Gaziano L, Sun L, Arnold M, Bell S, Cho K, Kaptoge SK, et al. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. Circulation. 2022 Nov 15;146(20):1507-1517.
NO The Emerging Risk Factors Collaboration (ERFC) coordinating center was underpinned by program grants from the British Heart Foundation (BHF; SP/09/002;RG/13/13/30194; RG/18/13/33946), BHF Centre of Research Excellence(RE/18/1/34212), the UK Medical Research Council (MR/L003120/1), andthe National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014), with project-specific support receivedfrom the UK NIHR, British United Provident Association UK Foundation, and anunrestricted educational grant from GlaxoSmithKline. This work was supported byHealth Data Research UK, which is funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic andSocial Research Council, the Department of Health and Social Care (England),the Chief Scientist Office of the Scottish Government Health and Social CareDirectorates, the Health and Social Care Research and Development Division(Welsh Government), the Public Health Agency (Northern Ireland), the BHF, andthe Wellcome Trust. A variety of funding sources have supported recruitment,follow-up, and laboratory measurements in the studies contributing data to theERFC, which are listed on the ERFC website (www.phpc.cam.ac.uk/ceu/erfc/list-of-studies). EPIC-CVD (European Prospective Investigation into Cancer andNutrition–Cardiovascular Disease Study) was funded by the European ResearchCouncil (268834) and the European Commission Framework Programme 7(HEALTH-F2-2012-279233). The coordination of EPIC is financially supportedby International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHRImperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut GustaveRoussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santéet de la Recherche Médicale (INSERM) (France); German Cancer Aid, GermanCancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF)(Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of PublicHealth, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland),World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands);Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and theCatalan Institute of Oncology - ICO (Spain); Swedish Cancer Society, SwedishResearch Council and County Councils of Skåne and Västerbotten (Sweden);Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council, United Kingdom (1000143 to EPIC-Norfolk;MR/M012190/1 to EPIC-Oxford). The establishment of the EPIC-InterActsubcohort (used in the EPIC-CVD study) and conduct of biochemical assayswas supported by the EU Sixth Framework Programme (FP6) (grant LSHM_CT_2006_037197 to the InterAct project) and the Medical Research CouncilEpidemiology Unit (grants MC_UU_12015/1 and MC_UU_12015/5). This research is based on data from the Million Veteran Program, Office of Research andDevelopment, and Veterans Health Administration and was supported by awardI01-BX004821 (principal investigators, Drs Peter W.F. Wilson and Kelly Cho) andI01-BX003360 (principal investigators, Dr Adriana M. Hung). Dr Damrauer issupported by IK2-CX001780. Dr Hung is supported by CX001897. Dr Tsao issupported by BX003362-01 from VA Office of Research and Development. DrRobinson-Cohen is supported by R01DK122075. Dr Sun was funded by a BHFProgramme Grant (RG/18/13/33946). Dr Arnold was funded by a BHF Programme Grant (RG/18/13/33946). Dr Kaptoge is funded by a BHF Chair award(CH/12/2/29428). Dr Mason is funded by the EU/EFPIA Innovative MedicinesInitiative Joint Undertaking BigData@Heart grant 116074. Dr Bolton was fundedby the NIHR BTRU in Donor Health and Genomics (NIHR BTRU-2014-10024).Dr Allara is funded by a BHF Programme Grant (RG/18/13/33946). Prof Inouye is supported by the Munz Chair of Cardiovascular Prediction and Prevention and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).Prof Inouye was also supported by the UK Economic and Social Research 878Council (ES/T013192/1). Prof Danesh holds a British Heart Foundation Professorship and a NIHR Senior Investigator Award. Prof Wood is part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 JointUndertaking under grant agreement No 116074. Prof Wood was supported bythe BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). Prof DiAngelantonio holds a NIHR Senior Investigator Award.
DS RISalud
RD Apr 11, 2025